ACP Letter of Support for the CREATES Act of 2016

ACP's letter in support of the bipartisan effort to craft the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016.

Prescription drug prices, generic drugs, biologics, biologicals, biosimilars, low-cost prescription drugs, brand-name prescription drugs, drug manufacturers, pharmaceutical companies, pharma, rising costs of prescription drugs, patient access to prescription drugs, Committee on the Judiciary, Sen. Chuck Grassley, Sen. Mike Lee, Sen. Patrick Leahy, Sen. Amy Klobuchar, Food and Drug Administration, FDA, CREATES Act of 2016, Risk Evaluation and Mitigation Strategies, REMS, Elements to Assure Safe Use, ETASU, prescription drug safety programs and protocols, medications

Fri, 06/10/2016 - 4:17 PM EDT

Tue, 06/14/2016 - 8:50 AM EDT

2

acp_support_creates_act_2016.pdf

{"CreationDate":"2016-06-10T16:17:31-04:00","Creator":"Microsoft\u00ae Word 2010","Keywords":"Prescription drug prices, generic drugs, biologics, biologicals, biosimilars, low-cost prescription drugs, brand-name prescription drugs, drug manufacturers, pharmaceutical companies, pharma, rising costs of prescription drugs, patient access to prescription drugs, Committee on the Judiciary, Sen. Chuck Grassley, Sen. Mike Lee, Sen. Patrick Leahy, Sen. Amy Klobuchar, Food and Drug Administration, FDA, CREATES Act of 2016, Risk Evaluation and Mitigation Strategies, REMS, Elements to Assure Safe Use, ETASU, prescription drug safety programs and protocols, medications","ModDate":"2016-06-14T08:50:06-04:00","Producer":"Microsoft\u00ae Word 2010","Title":"ACP Letter of Support for the CREATES Act of 2016","Pages":2,"dc:format":"application\/pdf","dc:creator":"","dc:title":"ACP Letter of Support for the CREATES Act of 2016","dc:subject":["Prescription drug prices","generic drugs","biologics","biologicals","biosimilars","low-cost prescription drugs","brand-name prescription drugs","drug manufacturers","pharmaceutical companies","pharma","rising costs of prescription drugs","patient access to prescription drugs","Committee on the Judiciary","Sen. Chuck Grassley","Sen. Mike Lee","Sen. Patrick Leahy","Sen. Amy Klobuchar","Food and Drug Administration","FDA","CREATES Act of 2016","Risk Evaluation and Mitigation Strategies","REMS","Elements to Assure Safe Use","ETASU","prescription drug safety programs and protocols","medications"],"xmp:createdate":"2016-06-10T16:17:31-04:00","xmp:creatortool":"Microsoft\u00ae Word 2010","xmp:modifydate":"2016-06-14T08:50:06-04:00","xmp:metadatadate":"2016-06-14T08:50:06-04:00","pdf:producer":"Microsoft\u00ae Word 2010","pdf:keywords":"Prescription drug prices, generic drugs, biologics, biologicals, biosimilars, low-cost prescription drugs, brand-name prescription drugs, drug manufacturers, pharmaceutical companies, pharma, rising costs of prescription drugs, patient access to prescription drugs, Committee on the Judiciary, Sen. Chuck Grassley, Sen. Mike Lee, Sen. Patrick Leahy, Sen. Amy Klobuchar, Food and Drug Administration, FDA, CREATES Act of 2016, Risk Evaluation and Mitigation Strategies, REMS, Elements to Assure Safe Use, ETASU, prescription drug safety programs and protocols, medications","xmpmm:documentid":"uuid:77034001-9d7d-451f-97f4-ecf1388a26f6","xmpmm:instanceid":"uuid:b58a1f3f-cb10-4784-8da9-17662415cc23"}

2016